
India Faces $1BN Export Loss Following EC Generics Ban
July 28, 2015.
India is set to suffer at least $1 billion of loss in export of pharmaceutical products this fiscal following the ban on around 700 generic drugs by the European Commission for alleged manipulation of clinical trials by the Hyderabad-headquartered contract research and clinical trials firm GVK Bio,
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.